Best of ASCO - 2014 Annual Meeting

 

Welcome

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2019 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

Preliminary result of phase II study of megestrol combined with 5-hydroxytryptamine 3 inhibitor and dexamethasone for the prevention of nausea and vomiting induced by high emetogenic chemotherapy.

Sub-category:
Health Promotion

Category:
Symptoms and Survivorship

Meeting:
2019 ASCO Annual Meeting

Abstract No:
e23049

Citation:
J Clin Oncol 37, 2019 (suppl; abstr e23049)

Author(s): Qiong Wu, Suxia Luo, Ning Li, Wenying Deng, Yijie Ma, Xinyi Yang; Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China; Department of Medical Oncology, Henan Cancer Hospital, Zhengzhou, China; Henan Cancer Hospital, Zhengzhou, China

Abstract Disclosures

Abstract:

Background: Chemotherapy-induced nausea and vomiting (CINV) is one of the most distressing treatment-related side effects and have a strong impact on treatment adherence. A triplet antiemetic regimen, which is composed of neurokinin-1 receptor antagonist (NK1 RA), 5-hydroxytryptamine 3 (5-HT3) inhibitor and dexamethasone, is recommended by current antiemetic guidelines. However, NK1 RA is not available in hospital and more expensive for Chinese patients. Megestrol is currently known as more effective appetite stimulants in patients with cachexia or loss of appetite, but its antiemetic properties are less well known. Therefore, the aim of this study was to further evaluate the efficacy and safety of megestrol for the prevention of CINV. Methods: Patients treated with high emetogenic chemotherapy (HEC) were randomly divided into experimental group and control group. The antiemetic regimen of control group: 5-HT3 inhibitor 5mg/d, dexamethasone 12mg/d1, 8mg/d2-4. The regimen of experimental group: the use of 5-HT3 inhibitor and dexamethasone was the same as that of control group, and each patient took megestrol 160mg orally from the first day of chemotherapy for 10 days. Digestive tract reactions were daily evaluated after beginning of HEC. Primary end point was rate of complete response to vomiting and nausea. Results: From September 7 to December 31, 2018, 60 patients were enrolled and randomized in the study. The delayed nausea and vomiting rates were significantly lower in experimental group than control group (nausea: 63.3% vs 83.3%; vomiting: 13.3% vs 33.3%; p< 0.00). The control group was significantly higher rate of Grade 3-4 vomiting than that of the experimental group (20% vs 0%, p< 0.01). Conclusions: Megestrol, combined with dexamethasone and 5-HT3 inhibitor, has been shown to be able to successfully control CINV and no increase side effects during HEC. Clinical trial information: ChiCTR1800017953.

GroupNumberDelayed vomiting rate (%)Delayed nausea rate (%)3-4 grade vomiting rate (%)
experimental group3013.333.30
control group3063.383.320.0
P-value< 0.00< 0.00< 0.01

 
Other Abstracts in this Sub-Category:

 

1. Effects of a structured intervention program to improve physical activity (PA) of adolescents and young adult cancer survivors (AYAs): Final results of the randomized Motivate AYA–MAYA trial.

Meeting: 2019 ASCO Annual Meeting Abstract No: 11518 First Author: Jannike Lisa Salchow
Category: Symptoms and Survivorship - Health Promotion

 

2. Association of obesity with breast cancer outcome in relation to cancer subtypes.

Meeting: 2019 ASCO Annual Meeting Abstract No: 11557 First Author: Ana Elisa Lohmann
Category: Symptoms and Survivorship - Health Promotion

 

3. Physiological and psychosocial effects of a highly structured exercise program on breast cancer survivorship.

Meeting: 2019 ASCO Annual Meeting Abstract No: 11558 First Author: Judy A. Tjoe
Category: Symptoms and Survivorship - Health Promotion

 

More...